Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exogen

This article was originally published in The Gray Sheet

Executive Summary

Closes $10 mil. private financing from combination of new investors and investors who participated in the West Caldwell, New Jersey firm's March 1993 $7.3 mil. initial private financing round. The company says the proceeds will "support an effective launch" of its Sonic Accelerated Fracture Healing System (SAFHS), which recently received premarket approval from FDA for the accelerated healing of new fractures in the lower arm and leg ("The Gray Sheet" Oct. 17, p. 10). Exogen also will use the funds to support clinical investigation of additional indications for SAFHS, such as treatment of hip fractures, spine fusions, and bony ingrowth into artificial joint replacements
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel